🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in India / NCT06929988
Starting soon Not applicable

A Clinical Study to Assess the Safety and Effectiveness of Test Product in Healthy Adult Human Subjects With Dry or Sensitive Skin

NCT06929988 · tracked via the Priya Life Science India tracker
Sponsor
SAVA Healthcare Limited
Phase
Not applicable
Started
2025-05-15
Last updated
2025-04-24

Condition(s) studied

Dry SkinSensitive Skin

Investigational drug(s) / intervention(s)

Creanz Lotion

Creanz Lotion: Mode of Usage: Apply sufficient quantity of Creanz Nourishing Body lotion to face and body for smooth and moisturised skin. Frequency: Twice a Day Route of Administration: Topical

Study summary

This exploratory, prospective, open-label, single-centre, safety, efficacy and in-use tolerability study of the test product in healthy adult human subjects with dry or sensitive skin.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age: 18 to 55 years (both inclusive) at the time of consent. * Sex: Healthy male and non-pregnant/non-lactating females. * Females of childbearing potential must have a self-reported negative pregnancy test. * Subject are generally in good health. * Subject with dry or sensitive skin at a time of screening. (Dermatological Assessment) * Subjects assessment site must be free of cuts, tattoos, scratches, abrasions, scars, uneven skin tone, sunburn, excessive tan, excessive hair or open wounds. * Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study. * If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation. * Subjects are willing to give written informed consent and are willing to come for regular follow up. * Subjects who commit not to use medicated skincare products other than the test product for the entire duration of the study. * Subject who have not participated in a similar investigation in the past three months. * Willing to use test product throughout the study period. Exclusion Criteria: * History of any dermatological condition of the skin diseases. * Subject with present condition of allergic response to any cosmetic product. * Subject having allergic response to the ink. * Presence of any broken, chapped, cut, irritated, or scraped skin at the application site. * Subjects under chronic medication (e.g. aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy etc.) that might influence the outcome of the study. * Subject having acne of severe incidence (presence of nodules, cysts or numerous pustules) which requires pharmaceutical or cosmeceuticals, herbal treatment. * Subjects who have applied topical treatment for at least 4 weeks and any systemic treatment for at least 3 months, before they participated in the study. * History of alcohol or drug addiction. * Subjects using other marketed products during the study period. * Any other condition which could warrant exclusion from the study, as per the dermatologist's/investigator's discretion. * Pregnant or breastfeeding or planning to become pregnant during the study period. * History of chronic illness which may influence the cutaneous state. * Subjects participating in other similar cosmetics, devices or therapeutic trials or skincare products within the last four weeks.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
NovoBliss Research Pvt.Ltd Ahmedabad Gujarat
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06929988 on ClinicalTrials.gov ↗ ← All trials in India